SomaLogic to Announce Third Quarter 2021 Financial Results

Rhea-AI Summary

SomaLogic, a leader in AI-driven proteomics, will announce its Q3 2021 financial results on November 15, 2021, before market open. The conference call, starting at 8:00 AM ET, will allow investors to discuss the results. To participate, domestic investors can dial (844) 535-4027, while international callers may use (270) 215-9487 with conference ID: 8689426. The event will also be available via a live audio webcast on SomaLogic's investor relations page.

Positive

• SomaLogic has run over 450,000 samples to date, showcasing its operational capacity.
• The company holds CLIA certification and CAP accreditation, indicating high-quality standards in laboratory testing.

Negative

• None.

BOULDER, Colo., Oct. 28, 2021 (GLOBE NEWSWIRE) -- SomaLogic, Inc., a leader in AI-data driven proteomics technology, today announced that it will report financial results for the third quarter 2021 before the market opens on Monday, November 15, 2021. Company management will host a corresponding conference call beginning at 8:00 a.m. Eastern Time.

Investors interested in listening to the conference call may do so by dialing (844) 535-4027 for domestic callers or (270) 215-9487 for international callers, using conference ID: 8689426. A live audio webcast and an archive of the presentation will be available through the Investors page of SomaLogic’s corporate website at https://investors.somalogic.com/.

About SomaLogic
SomaLogic seeks to deliver precise, meaningful, and actionable health-management information that empowers individuals worldwide to continuously optimize their personal health and wellness throughout their lives. This essential information, to be provided through a global network of partners and users, is derived from SomaLogic’s personalized measurement of important changes in an individual’s proteins over time. For more information, visit www.somalogic.com and follow @somalogic on Twitter.

SomaSignal™ tests are developed and their performance characteristics determined by SomaLogic, Inc. SomaLogic is a Clinical Laboratory Improvement Amendments (CLIA) certified, and College of American Pathologists (CAP) accredited laboratory. 

The SomaScan Platform is for Research Use Only (RUO) and has not been cleared or approved by the US Food and Drug Administration for diagnostic or patient management purposes. SomaLogic’s proprietary SomaScan Platform was designed to be a universal platform that can be applied across research and discovery, translational research and biopharmaceutical development, and clinical applications. SomaLogic can run approximately 7,000 protein measurements on a single 55 microliter plasma or serum sample. The Company has run more than 450,000 samples to date.

SomaLogic Contact        
Emilia Costales
720-798-5054
ecostales@somalogic.com

Investor Contact
Marissa Bych or Lynn Lewis
Gilmartin Group LLC
investors@somalogic.com         

FAQ

What are SomaLogic's Q3 2021 financial results release date?

SomaLogic's Q3 2021 financial results will be reported on November 15, 2021.

How can I listen to SomaLogic's conference call for Q3 2021 results?

You can listen to the conference call by dialing (844) 535-4027 for domestic calls or (270) 215-9487 for international calls using conference ID: 8689426.

What time is the SomaLogic conference call for Q3 2021 results?

The conference call will begin at 8:00 AM Eastern Time on November 15, 2021.

Where can I find the SomaLogic Q3 2021 financial results webcast?

The webcast will be available on SomaLogic's investor relations page on their corporate website.